K2 HealthVentures Affiliate Acquires VBI Vaccines
January 3, 2025
K2 VBI Equity Trust, LLC, an affiliate of K2 HealthVentures LLC, completed the purchase of VBI Vaccines Inc. pursuant to an amended acquisition agreement and the Company's creditor protection proceedings under Canada's CCAA. Following closing, VBI and certain subsidiaries became wholly owned by the purchaser, all common shares were redeemed and cancelled, and VBI's directors and executive officers were replaced by nominees of K2; the company is expected to cease being a reporting issuer in Canada and to deregister its U.S. public filings.
- Buyers
- K2 VBI Equity Trust, LLC, K2 HealthVentures LLC
- Targets
- VBI Vaccines Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Venture Life Group plc Acquires BBI Healthcare (BBIH) from Exponent
June 7, 2021
Consumer Products
Venture Life Group plc has agreed to acquire BBI Healthcare (BBIH), the consumer self-care division of BBI Group, from private equity owner Exponent. BBIH — owner of brands including Balance Activ, GlucoGel and LIFT with broad UK retail distribution and a Swedish manufacturing facility — was transformed under Exponent, delivering strong EBITDA growth; its managing director will leave on completion while the chairman will remain with BBI Group.
-
Merck & Co., Inc. Acquires VelosBio Inc.
November 5, 2020
Biotechnology
Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.
-
Sanofi to Acquire Vicebio for Up to $1.6 Billion
July 25, 2025
Biotechnology
Sanofi will acquire clinical-stage biopharmaceutical company Vicebio in a deal worth up to $1.6 billion, including $1.15 billion upfront and $450 million in milestone payments. Vicebio, created by Medicxi using the University of Queensland's Molecular Clamp technology, develops multivalent vaccines targeting respiratory viruses and recently advanced a bivalent RSV/hMPV candidate into Phase 1 trials.
-
Kyyba Inc. Acquires Viki Technologies
March 16, 2023
Healthcare Services
Kyyba Inc./Kyyba Tech has agreed to acquire Viki Technologies, a specialist healthcare technology provider based in Farmington Hills, Michigan, for an undisclosed amount. The acquisition expands Kyyba's healthcare capabilities and will integrate Viki's clinical decision support and data-driven tools into Kyyba's broader healthcare solutions platform.
-
KKR-backed Biosynth Carbosynth Acquires vivitide; Ampersand Rolls Over Stake
March 17, 2022
Biotechnology
KKR has invested in Biosynth Carbosynth through its Health Care Strategic Growth Fund II, and Biosynth Carbosynth has acquired vivitide, a global provider of custom peptides and antibody services. Existing owner Ampersand Capital Partners rolled over its entire stake and will be a substantial minority shareholder in the combined global life‑sciences reagents and custom synthesis platform to accelerate geographic expansion, broaden capabilities, and expand the product portfolio.
-
Sobi Acquires CTI BioPharma Corp.
June 26, 2023
Biotechnology
Swedish Orphan Biovitrum AB (Sobi) completed the acquisition of CTI BioPharma Corp. through a cash tender offer and subsequent merger, paying USD 9.10 per share for a transaction valued at up to USD 1.7 billion. CTI, a Seattle-based biopharmaceutical company with the FDA-approved product VONJO and ~144 employees, becomes an indirect wholly owned subsidiary of Sobi and will be delisted from NASDAQ.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.